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Background Development of influenza vaccines capable of
inducing broad protection against different virus subtypes is
necessary given the ever-changing viral genetic landscape.
Previously, we showed that vaccination with whole inactivated virus
(WIV) induces heterosubtypic protection against lethal virus
infection in mice. Whole inactivated virus-induced cross-protection
was found to be mediated primarily by flu-specific CD8+ T cells.
Objectives As it has been demonstrated that the route of vaccine
administration strongly influences both the quantity and quality of
vaccine-induced immunity, in this study, we determined which
route of WIV administration induces optimal heterosubtypic cross-
protection.
Methods We compared the magnitude of the immune response
and heterosubtypic protection against lethal A/PR/8/34 (H1N1)
infection after subcutaneous (SC), intramuscular (IM), and
intranasal (IN) vaccination with A/NIBRG-14 (H5N1) WIV.
Results Subcutaneous and IM administration was superior to IN
administration of influenza WIV in terms of flu-specific CD8+
T-cell induction and protection of mice against lethal
heterosubtypic challenge. Surprisingly, despite the very low flu-
specific CD8+ T-cell responses detected in IN-vaccinated mice, these
animals were partially protected, most likely due to cross-reactive
IgA antibodies.
Conclusion The results of this study show that the magnitude of
WIV-induced flu-specific CD8+ T-cell activity depends on the
applied vaccination route. We conclude that parenteral
administration of WIV vaccine, in particular IM injection, is
superior to IN vaccine delivery for the induction of heterosubtypic
cross-protection and generally appears to elicit stronger immune
responses than mucosal vaccination with WIV.
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Introduction
Annual influenza epidemics represent a major cause of
morbidity and mortality worldwide.1 Occasionally, as a result
of antigenic shift, a new influenza virus subtype, which is not
recognized by antibodies induced by previous infection or
vaccination, appears in the human population. In the
absence of specific immunity, such viruses can be transmitted
rapidly to cause global pandemics.2
Influenza vaccines have substantially reduced the burden of
disease due to influenza infection, especially in vulnerable
groups, such as the elderly and patients with chronic respira-
tory or cardiovascular disease.3,4 Although vaccination still
represents the best way to prevent influenza, there is an urgent
need for improvement. Current vaccination approaches aim to
induce antibody responses against the variable viral surface
antigens, mainly hemagglutinin (HA). Consequently, the
overall success of seasonal vaccination depends mainly on
the antigenic match between the vaccine and the circulating
virus strain and may vary substantially from one season to the
next.5,6 The antigenic composition of an emerging pandemic
virus cannot be predicted at all, which makes it difficult to
prepare sufficient vaccine stocks in due time.6 To restrict the
impact of “between-season” strain variability and to attenuate
the threat of a pandemic influenza outbreak, cross-protective
influenza vaccines are desirable. Such vaccines should ideally
target conserved viral antigens, such as the internal nucleo-
protein (NP) or the matrix protein (M1).7,8
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Previously, we demonstrated that vaccination with whole
inactivated virus (WIV), but not with subunit or split-virion
vaccines, can protect mice from lethal heterosubtypic influ-
enza challenge. This protection was due to the induction of a
potent CD8+ T lymphocyte response against conserved virus
proteins, such as NP.9
In addition to the nature of the antigen and the presence
of an adjuvant, the route of administration can strongly
influence the immunogenicity of a vaccine.10–12 For example,
intranasally administered virus-like particles (VLPs) express-
ing influenza M2 protein induce superior antibody responses
compared with the same vaccine administered subcutane-
ously.12
Here, we investigated which route of WIV administration
optimally induces heterosubtypic cross-protection against
influenza. Specifically, we compared parenteral routes of
administration (subcutaneous, SC; intramuscular, IM) with a
mucosal vaccination route (intranasal, IN). After adminis-
tration of H5N1 WIV, we determined the survival of mice
after heterosubtypic challenge with H1N1 virus and mea-
sured the magnitude of induced flu-specific CD8+ T-cell
responses. The main finding of the study is that full
protection against lethal heterosubtypic challenge in mice
was obtained only when WIV was delivered through one of
the parenteral routes. The protection correlated with the
presence of flu-specific CD8+ T cells. Only partial protection
was observed in IN-vaccinated mice, which mounted very
poor flu-specific CD8+ T-cell responses but developed cross-
neutralizing IgA antibodies.
Materials and methods
Virus strains and vaccine preparation
Vaccine virus (NIBRG-14/H5N1, a 6:2 reassortant strain of A/
PR/8/34 and A/Vietnam/1194/2004) was cultured on Madin–
Darby canine kidney (MDCK) cells. Challenge virus (A/PR/8/
34 H1N1), cultured in eggs, was a kind gift from Solvay
Biologicals (Weesp, the Netherlands). Whole inactivated virus
vaccine was prepared by inactivation of the virus with 01%
b-propiolactone (BPL) for 24 hours at room temperature,
followed by dialysis for 24 hours against HNE buffer (5 mM
HEPES, 150 mM NaCl, 01 mM EDTA, pH 74). Inactivation
of the vaccine was tested as described previously.13
Vaccination and challenge
Mouse experiments were performed in accordance with
Dutch legislation on animal experiments and were approved
by the Ethics Committee on Animal Research of the
University Medical Center Groningen (permit number:
5101B). Vaccination, blood sampling, challenge, and eutha-
nasia were performed under isoflurane anesthesia.
Female C57BL/6 mice, 6–8 weeks old, were purchased
from Harlan, the Netherlands. Each vaccination group
consisted of 12 mice that were divided into two subgroups.
One of the subgroups was monitored for body weight change
over a period of 2 weeks post-challenge. Mice from the other
subgroup were euthanized 6 days post-challenge for analysis
of lung virus titers and immune response parameters. On
days 0 and 21, mice received two doses of 20 lg of total WIV
protein administered (i) SC, 200 ll in the neck area; or (ii)
IM, 25 ll in the right hind leg, or (iii) IN, 40 ll equally
distributed into both nostrils. Using this procedure, some
part of the IN-inoculated volume may distribute further
down to the lower respiratory tract or the gastrointestinal
tract. Non-vaccinated mice served as controls. One week
after the booster, mice were anesthetized and inoculated IN
with 100 TCID50 of PR8 virus in a total volume of 40 ll.
Viral TCID50 was determined according to a previously
published protocol.9,14 In brief, lungs were dissected,
homogenized, and stored at 80°C until further use. Virus
titers were determined by adding serial dilutions of the
clarified homogenates to MDCK cells in 96-well plates and
culturing the cells in the presence of TPCK trypsin. The
highest dilution of culture supernatant that still showed
hemagglutination activity was taken as the virus titer in the
lungs. Titers are indicated as 10 log virus titer per gram of
lung tissue.
Upon challenge, mice were monitored for disease symp-
toms (i.e., ruffled fur and weight loss). Loss of more than
20% of the total body weight during the 2-week post-
challenge period was an indication for euthanasia.
Tetramer staining of blood, spleen, lymph node,
and lung lymphocytes
Tetramer stainings on blood, spleen, lymph node, and lung
lymphocytes were performed as described before.9 In brief,
lymphocytes were isolated from the tissues using previously
described methods9 and washed with FACS buffer (1%
BSA, 5 mM EDTA in PBS). Cells were then stained with
anti-mouse CD8a-APC antibody (ImmunoSource, Schilde,
Belgium) and influenza NP366-374-tetramer-PE.
9 Dead cells
were excluded using 7AAD viability solution (Immuno-
Source). Flow cytometric analysis was performed using a
FACS Calibur flow cytometer (BD Biosciences, Breda, the
Netherlands).
Influenza-specific IgG and IgA ELISA
ELISA was performed as described before.9,13 In brief,
microtiter plates were coated overnight with 05 lg of
influenza H5N1 (NIBRG-14) or H1N1 (PR/8) WIV per well.
Plates were then blocked, washed, and incubated with
twofold serial dilutions of serum or vaginal wash samples
for 15 hour at 37°C. After washing, plates were incubated
for 1 hour with HRP-conjugated goat anti-mouse IgG or
IgA antibody (Southern Biotech, Birmingham, AL, USA)
followed by 30-min staining with o-phenylene-diamine
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staining solution. The reaction was stopped by adding 50 ll
per well of 2 M H2SO4, and the absorbance was read at
492 nm.
Microneutralization assay
Microneutralization assays were performed as described
before.9 In brief, twofold serial dilutions of sera were added
to 50 TCID50 of A/PR/8 virus and incubated for 2 hours at
37°C. Mixtures of serum and virus were then added to
MDCK cells in 96-well plates. After 1-hour incubation at
37°C, culture supernatants were replaced by medium sup-
plemented with 6 lg/ml of TPCK trypsin and cells were
incubated for an additional 72 hours. Supernatants were
harvested and tested for hemagglutinating activity. The
highest dilution of serum preventing virus infection was
taken as the neutralizing titer.
Statistical methods
To determine the differences between vaccination groups with
respect to flu-specific CD8+ T-cell frequencies, influenza
antibody titers, and lung virus titers, the Mann–Whitney
U-test with a confidence interval of 95% was used. A value
of P < 005 was considered statistically significant and is
designated in the figures with an asterisk. Double and triple
asterisks indicate P values of <001 and <0001, respectively.
Results
Heterosubtypic cross-protection induced by WIV
administered through different vaccination routes
To evaluate the impact of different vaccination routes (SC,
IM, and IN) on the efficacy of WIV-induced heterosubtypic
cross-protection, mice were vaccinated twice with WIV
derived from A/NIBRG-14 (H5N1) virus and subsequently
challenged with A/Puerto Rico/8/34 (PR8) influenza virus, an
H1N1 strain. Seven days after the booster vaccination, mice
were exposed to heterosubtypic challenge with 100 TCID50
of live PR8 and monitored daily for body weight loss. During
this post-challenge period, IM-vaccinated mice experienced
only minor body weight loss (Figure 1). Three of six SC-
vaccinated mice lost up to 12% of their body weight, after
which they recovered. Four of six mice vaccinated via the IN
route lost more than 15% of their body weight, and one of
them had to be euthanized. Non-immune mice experienced
rapid weight loss and disease symptoms necessitating eutha-
nasia by day 6 post-challenge (Figure 1).
Influence of the route of vaccine administration on
lung virus clearance
To investigate the influence of different administration
routes on vaccine-induced clearance of virus from the lungs,
mice were vaccinated and challenged according to the
schedule described above and sacrificed 6 days post-chal-
lenge for lung viral titer assessment. Virus titers in the lungs
of SC-vaccinated mice were significantly lower compared
with titers in lungs of non-vaccinated mice. Vaccination with
WIV via the IM route resulted in an even more pronounced
decrease in titers (Figure 2). In contrast, virus titers in the
lungs of IN-vaccinated mice were not significantly reduced
compared with titers measured in the lungs of non-immune
mice, although a trend toward lower titers was apparent
(Figure 2). Fourteen days post-challenge, virus titers in the
lungs of all surviving mice were undetectable, irrespective of
the route of vaccination (data not shown).
Figure 1. Body weight change and survival of
WIV-vaccinated mice after heterosubtypic
challenge. Mice received two doses of 20 lg
(total viral protein) NIBRG-14 (H5N1) WIV,
administered subcutaneously (SC),
intramuscularly (IM), or intranasally (IN). Non-
vaccinated mice were used as controls. After
the booster vaccination, mice were exposed to
lethal heterosubtypic challenge with 100
TCID50 A/PR8 (H1N1) virus and monitored
daily for body weight change over the
following 2 weeks. Experiments were
performed twice. A body weight loss of more
than 20% was an indication for euthanasia
(dashed line).
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Influence of the route of vaccine administration on
WIV-induced flu-specific CD8+ T-cell responses
Earlier, we showed that the main mediators of heterosubtypic
cross-protection induced in mice by SC administration of
WIV are flu-specific CD8+ T cells.9 Therefore, we evaluated
the impact of different vaccine administration routes on the
magnitude of the induced flu-specific CD8+ T-cell response.
To this end, mice were vaccinated according to the schedule
described above. One week after the booster vaccination,
immediately prior to challenge, peripheral blood NP366-374
tetramer+ CD8+ cells were measured. Six days post-chal-
lenge, tetramer staining was also performed on cells from
spleen, lungs, and lymph nodes draining the vaccine injection
site (cervical for IN and SC injections; inguinal for IM
injection).
Whole inactivated virus administered through the IM
route induced significantly higher NP-specific CD8+ T-cell
responses in blood, spleen, lung, and draining lymph nodes
compared with levels induced by IN administration (Fig-
ure 3A–D). There were no significant differences in NP-
specific CD8+ T-cell frequencies measured in the spleens,
lungs, and lymph nodes of IM-vaccinated and SC-vaccinated
mice on a per site basis (Figure 3B–D). However, in pre-
challenge blood, NP-specific CD8+ T-cell frequencies were
significantly higher in IM-vaccinated compared with SC-
vaccinated mice (Figure 3A). Vaccination via the IN route
induced low numbers of NP-specific CD8+ T-cells, which
only in spleen were significantly higher as compared to non-
vaccinated mice (Figure 3B). Thus, flu-specific CD8+ T-cell
responses are induced more efficiently by parenteral
compared with mucosal delivery of WIV.
Influence of the route of vaccine administration on
WIV-induced antibody responses
To evaluate humoral immune responses induced by vacci-
nation with WIV administered through different routes, we
measured influenza-specific IgG and IgA antibody titers in
pre-challenge blood. Additionally, antibody titers were
measured in pre-challenge vaginal washes; sampling of
vaginal lavages provides access to a mucosal site without
requiring euthanasia. It has been demonstrated that antibody
titers (IgA) measured in vaginal washes correlate closely with
antibody titers measured at other mucosal surfaces, including
Figure 2. Lung virus titers after vaccination and heterosubtypic
challenge. Virus titers in the lungs of mice vaccinated with H5N1 WIV,
delivered via the indicated routes, and challenged with H1N1 virus, as in
Figure 1, were measured 6 days post-challenge. Experiments were
performed twice. Bars represent mean titerSEM of three mice per
group. *P < 005; Mann–Whitney U-test.
A B
C D
Figure 3. Flu-specific CD8+ T-cell responses
induced by vaccination with WIV administered
through different routes. Mice were vaccinated
with H5N1 WIV via the indicated routes, as in
Figure 1. Flu-specific CD8+ T cells were
measured by NP366-374 tetramer staining in
PBMCs pre-challenge (A) and in spleens (B),
local lymph nodes (C), and lungs (D) 6 days
post-challenge with H1N1 virus, as in Figure 1.
Experiments were performed twice. Bars
represent mean CD8+ tetramer+ cell numbers
per 106 cells  SEM of six mice per group for
PBMCs, spleens, and lymph nodes and three
mice per group for lungs. *P < 005;
**P < 001; Mann–Whitney U-test.
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lung.15 Using ELISA, we assessed IgG and IgA levels specific
for the vaccine virus (NIBRG-14/H5N1) and for the
challenge virus (PR8/H1N1). As a positive control for
PR8-specific antibodies, pooled sera of mice primed
intraperitoneally with replicating PR8 virus were used.
The highest IgG antibody titers against homologous
(H5N1) and heterologous (H1N1) virus were induced by
IM administration of WIV (Figure 4A). In contrast, WIV
administered through the SC or IN routes induced low-
serum IgG antibody titers against H5N1 virus and
barely detectable titers against the H1N1 challenge virus
(Figure 4A). A similar pattern was observed in vaginal
washes. Four of six mice from the IM group had detectable
mucosal IgG antibody titers against both the vaccine and the
challenge virus; in contrast, only two of six mice from the SC
group had detectable IgG titers and these were substantially
lower (Figure 4B). Influenza-specific mucosal IgG titers were
not detectable in mice vaccinated through the IN route
(Figure 4B).
In contrast to IgG antibodies, which were found in all
vaccination groups (with the exception of vaginal washes from
the IN group), IgA antibodies were detected only in sera and
vaginal washes from IN-vaccinated mice (Figure 4C, D).
Virus neutralization by antibodies induced upon
administration of WIV through different
vaccination routes
To determine whether antibodies induced by vaccination
with WIV could potentially play a role in virus neutralization
and protection from heterosubtypic challenge, we performed
a microneutralization assay with PR8 virus using pre-
challenge sera and vaginal washes obtained from immunized
animals. Sera from mice immunized through the SC or IM
routes displayed only minimal neutralization activity against
the PR8 challenge virus (Figure 5). In contrast, sera obtained
from IN-vaccinated mice neutralized the challenge virus with
10-fold greater efficacy. None of the tested vaginal washes
exhibited neutralizing activity, most likely due to antibody
dilution (data not shown). Collectively, these observations
suggest that IgA, but not IgG, antibodies could play a role in
the partial heterosubtypic cross-protection observed after IN
vaccination.
Discussion
In a previous study, we demonstrated that immunization of
mice with influenza WIV vaccine provides protection against
heterosubtypic challenge, primarily through the induction of
cross-reactive flu-specific CD8+ T-cell responses.9 Here, we
show that parenteral administration, particularly IM injec-
tion, is superior to mucosal (IN) vaccine delivery for the
induction of cross-reactive flu-specific CD8+ T-cell responses
and cross-protection by WIV. However, mucosal immuni-
zation, as compared to IM or SC injection, induces a superior
secretory IgA (SIgA) response, which may also contribute to
heterosubtypic protection.
Our conclusion that parenteral vaccine administration is
superior to mucosal delivery in terms of CD8+ T-cell
priming is consistent with observations in several other
systems. For example, Bessa et al.12 showed that virus-like
particles containing a peptide derived from lymphocytic
choriomeningitis virus induced a superior cellular immune
response when the vaccine was administered through SC
injection compared with mucosal administration. Further-
more, Decrausaz et al.16 observed that CD8+ T-cell responses
were induced more effectively by parenteral rather than
A B
C D
Figure 4. Total influenza-specific systemic and
mucosal IgG and IgA antibodies. ELISA plates
were coated with vaccine (H5N1) or challenge
(H1N1) virus. Titers of influenza-specific IgG
and IgA antibodies against both viruses were
measured in pre-challenge sera and vaginal
washes obtained from mice vaccinated as in
Figure 1. As a positive control, pooled sera
obtained from mice primed intraperitoneally
with live PR8 (H1N1) virus were used.
Experiments were performed twice. Bars
represent mean antibody titers SEM of six
mice per group. **P < 001; Mann–Whitney
U-test.
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mucosal administration of a human papillomavirus vaccine.
In addition, in early studies on the induction of flu-specific
CD8+ T-cell activity by isolated NP, the antigen was
administered IM or SC.17
There are several potential explanations for the limited
capacity of inactivated vaccines to induce CD8+ T-cell
responses when administered mucosally. First, antigens
delivered to mucosal surfaces are likely to be diluted in
mucosal secretions and or quickly removed, limiting their
availability for immune recognition.18,19 Importantly, low
antigen availability is a limiting factor for cross-presentation
and CD8+ T-cell induction.20 Also, antigen delivered
through mucosal versus parenteral administration engages
DCs with different cross-presenting capacities.21,22 Finally,
mucosal immunization, as a consequence of the phenome-
non of mucosal tolerance, may suppress the induction of
systemic cellular responses.23–25
There appears to be a major difference between replicative
and inactivated influenza vaccines in terms of their ability to
induce CD8+ T-cell responses upon mucosal delivery to the
respiratory tract. Several studies in mice,26 ferrets,27 and non-
human primates28 have shown that mucosal administration,
in particular pulmonary delivery,29 of infectious virus,
resulting in a non-lethal infection of the (lower) respiratory
tract, is very effective at inducing robust CD8+ T-cell
responses and mediating cross-protection upon subsequent
challenge with divergent virus variants or subtypes.30 Indeed,
establishment of a pulmonary infection appears to be more
effective at inducing flu-specific CD8+ T-cell responses than
priming via the intraperitoneal, intravenous, or IN routes.29
In contrast, mucosal delivery of inactivated vaccines induces
mainly SIgA antibodies, but not flu-specific CD8+ T-cell
responses.31 Presumably, the barriers that impede the
efficient development of T-cell responses upon mucosal
delivery of inactivated vaccines do not affect replicative
vaccines to the same extent. Productive infection results in
the generation of comparatively high doses of viral antigen.
In addition, active virus replication triggers DC activation,
promotes the presentation of viral antigens in the context of
both class I and class II MHC molecules, and may readily
overcome mucosal tolerance.32 It is interesting in this respect
that mucosal delivery of infectious influenza virus, as well as
a recombinant adenovirus vector expressing influenza NP
antigen, was more effective at inducing heterosubtypic cross-
protection than IM injection.33
Our finding that mucosal administration of influenza WIV
vaccine is suboptimal for the induction of CD8+ T-cell
immunity is at variance with findings from Alsharifi et al.34
They compared heterosubtypic protection induced by c ray-
inactivated WIV (c-WIV) using different administration
routes and found that IN administration was superior to SC
delivery. In our hands, however, SC injection of WIV
induced solid cross-protection that correlated closely with
the magnitude of the NP-specific CD8+ T-cell response,
while mucosal administration provided only partial protec-
tion that appeared to be mediated primarily by cross-reactive
SIgA. It is difficult to explain this apparent discrepancy. It is
unlikely that the dose of antigen was lower in our study,
although a direct comparison of doses cannot be made.
Alsharifi et al. measured antigen dose in pfu equivalents,
whereas we used protein concentration. Nonetheless, a
conservative estimate would suggest that the antigen dose
was substantially higher in our study. It is possible that the
protection observed in the study by Alsharifi et al.34 was
mediated by cross-reactive antibodies, which were not
investigated. Another important variable could be the use
of different inactivation protocols for producing WIV;
different inactivation protocols may yield vaccine formula-
tions with varying capacities to activate cytosolic innate
receptors and to induce cross-protective T-cell responses.9,35
Also, it is possible that the c-WIV used by Alsharifi et al. was
not entirely devoid of replication-competent virus, which, as
discussed above, is very efficient in inducing CD8+ T-cell
responses upon delivery to the respiratory tract. In this
respect, it is interesting to note that infectivity of apparently
completely inactivated c-WIV may be reconstituted through
genetic complementation.36 Indeed, upon multiple infection
of a single cell, viral particles critically damaged at different
parts of the genome may complement each other thereby
reconstituting the capacity to produce infectious virus
particles. A similar phenomenon has recently been described
in a study by Brooke et al.,37 showing that influenza virus
often exists as a population of “abortive infectious forms” of
virus that, through multiple infection, may reconstitute
infectivity. A comparative study, involving head-to-head
testing of similar doses of BPL-inactivated WIV or c-WIV
administered through different routes, would help to clarify
the discrepancy between our findings and the findings by
Alsharifi et al.34
Figure 5. H1N1 virus-neutralizing antibodies. Pre-challenge sera from
mice vaccinated with H5N1 WIV, administered through the indicated
routes, as in Figure 1, were tested for the presence of antibodies capable
of neutralizing the H1N1 challenge virus. As a positive control, pooled
sera obtained from mice primed intraperitoneally with live PR8 (H1N1)
virus were used. Experiments were performed twice. Bars represent mean
titers SEM of six mice per group. ***P < 0001; Mann–Whitney U-test.
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Our data are also at apparent variance with those of
Bodewes et al.38 In the present study, IM injection of WIV
induced robust cross-protective flu-specific CD8+ T-cell
responses, whereas Bodewes et al. observed minimal flu-
specific CD8+ T-cell induction and, as a result, no hetero-
subtypic cross-protection after IM vaccination of mice with
formaldehyde-inactivated WIV.38 This apparent discrepancy
may be explained by the use of divergent virus inactivation
protocols and the use of different combinations of vaccine
strain and challenge strain. As we showed previously,9,13
virus inactivation procedures using formaldehyde severely
compromise the membrane fusion activity of WIV particles,
which results in a significant decrease in the CD8+ T-cell-
priming capacity of the vaccine. We prepared WIV using
BPL as the inactivating agent, which preserves viral mem-
brane fusion activity and, consequently, the CD8+ T-cell-
priming ability of the vaccine to a considerable extent.9
Another variable that could explain the variance of our
findings with findings of Bodewes et al. is the use of
different combinations of vaccine strain and heterosubtypic
challenge strain. Bodewes et al. used a reassortant H3N2
vaccine strain and a H5N1 A/IND challenge strain,38 while
we used a reassortant H5N1 vaccine strain and a H1N1 A/
PR8 challenge strain. The H5N1 reassortant contains
internal virus proteins derived from A/PR8. While this
optimizes internal viral antigen recognition by flu-specific
CD8+ T cells, this model may not optimally reflect
challenges that are faced in induction of cross-protection
in humans.
Although mucosal administration of inactivated vaccine
was suboptimal for the induction of flu-specific CD8+ T-cell
activity in our experiments, we did observe partial protection
from heterosubtypic challenge in mice immunized IN with
WIV. The observed protection correlated with the presence
of SIgA antibodies in mucosal secretions and cross-neutral-
izing serum antibodies which were found only after IN
immunization, although it should be noted that the levels of
antibodies in the vaginal washes might not fully reflect those
of the respiratory organs. Sera of IM-immunized mice
contained only IgG antibodies and did not show any in vitro
neutralizing capacity (Figures 4A, B and 5). These results are
in agreement with observations of others. Indeed, several
studies have demonstrated the induction of full or partial
protection against homosubtypic or heterosubtypic influenza
infection by vaccination through a mucosal route and have
also shown a close correlation between protection and the
presence of mucosal SIgA antibodies.31,39–41 To establish
whether a higher level of local protection (i.e., nasal cavity) is
induced by IN immunization using WIV, a lower volume of
challenge virus than used in the present study would be
preferred. In this respect, aerosol inoculation of virus, for
example, could mimicked natural influenza infection more
closely.
In conclusion, the route of administration substantially
influences the induction of cross-reactive flu-specific CD8+
T-cell responses and heterosubtypic cross-protection induced
by influenza WIV in mice. Parenteral delivery of WIV, in
particular IM vaccination, induces superior cross-reactive
CD8+ T-cell responses and cross-protection compared with
mucosal vaccine administration. On the other hand, anti-
body responses induced by mucosal (IN) vaccination with
WIV, in particular SIgA, can contribute to heterosubtypic
cross-protection in the absence of optimal flu-specific CD8+
T-cell immunity. Nonetheless, we conclude that parenteral
vaccination is preferable for the induction of heterosubtypic
cross-protection against influenza using WIV. Currently used
vaccines either lack conserved target antigens for CD8+ T
cells (e.g., subunit vaccines) or lack intrinsic adjuvant
components such as viral RNA (e.g., subunit and split virus
vaccines) that could help to boost (cellular) immunity
through TLR7/8 activation. WIV, however, contains both
conserved target antigens for CD8+ T cells and TLR-
activating components and therefore holds promise as a
candidate cross-protective influenza vaccine for use in
humans. The findings from this study may further guide
the development and implementation of such a cross-
protective vaccine.
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